No, a high IgG level does not mean you have cancer. Immunoglobulin G (IgG) is the most abundant antibody class in your blood, and elevated levels most often reflect infection, inflammation, autoimmune disease, or liver and kidney conditions. Cancer can raise IgG in a few specific situations, but it is neither a common nor a reliable marker for malignancy. Doctors diagnose cancer with biopsy, imaging, and tumor-specific tests, never with a total IgG count alone.

What IgG Actually Measures

IgG is a protein your plasma cells make in response to antigens. Each molecule has two heavy chains and two light chains arranged in a Y shape. The variable tips of that Y bind a specific target, and the constant stem tells immune cells what to do with it. A total IgG test counts all of these molecules together. It does not distinguish antibodies against measles from antibodies against a harmless gut bacterium.

That distinction matters because the test is quantitive, not diagnostic. A pooled number can rise when one clone of plasma cells expands, when many clones expand at once, or when IgG is lost more slowly than it is made. Each scenario has a different meaning.

Production depends on B-cell maturation. Naive B cells that meet their antigen in a lymph node enter germinal centers and switch from IgM to IgG. They then become memory cells or antibody-secreting plasma cells. A sustained rise in total IgG usually means more plasma cells are active somewhere in the body. The test cannot tell you where.

Clearance matters too. IgG is broken down partly in the liver and partly by cells that recycle antibodies through a receptor called FcRn. Liver disease or kidney disease can shift the balance, sometimes raising measured levels without a true increase in production. Plainly, a high IgG result is a signal about immune activity, not a cancer test.

How Cancer Could Raise IgG — and How Rarely It Does

Cancer could affect IgG through three main routes. The first is chronic immune stimulation. A tumor can trigger persistent inflammation, and persistent inflammation can drive antibody production. This is indirect and inconsistent. Many cancers produce no measurable IgG change at all.

The second route is a plasma cell cancer. Multiple myeloma is a malignancy of antibody-producing plasma cells. It usually secretes a single monoclonal protein, detected as an M-spike on protein electrophoresis. That M-spike is often IgG, but about 20 percent of myelomas produce IgA, and some produce only light chains. A high total IgG can appear here, yet the diagnostic test is electrophoresis with immunofixation, not a total IgG count.

The third route is a paraneoplastic antibody response. Some tumors provoke antibodies that attack the nervous system, such as anti-Hu or anti-NMDA receptor antibodies. These are specific, low-volume, and found with dedicated tests. They do not usually push total IgG above the reference range.

The counterintuitive point: the highest IgG levels in clinical practice most often come from non-cancerous conditions. Chronic infections and autoimmune diseases dwarf cancer as causes. A very high number pushes clinicians toward infection or inflammation first, not malignancy.

What Counts as High: Numbers and Ranges

Laboratories set their own reference ranges, but adult total IgG commonly falls near 600 to 1,600 mg/dL. Some labs use 700 to 1,600 mg/dL. A value above the upper limit is flagged high, and mild elevations of 10 to 20 percent above cutoffs are common and often transient.

Severity is usually graded by how far the value sits above the upper limit. A level just 15 percent high deserves a repeat test in several weeks. A level two or three times the upper limit deserves a workup for the cause. Values above 3,000 mg/dL appear in chronic infections, autoimmune disease, and some plasma cell disorders.

Testing units vary internationally. In the United States, IgG is usually reported in mg/dL, while some countries use g/L. One g/L equals 100 mg/dL. Mixing these units is a common source of false alarm.

A single number carries little weight without context. The pattern of immunoglobulins, age, symptoms, and prior results matter more than the peak value. Repeated measurement turns a snapshot into a trend, and trends change interpretation.

The IgG Subclass Detail Most Articles Skip

Total IgG is a sum of four subclasses: IgG1, IgG2, IgG3, and IgG4. They differ in structure, function, and normal levels. IgG1 makes up roughly 60 to 70 percent of total IgG, IgG2 about 20 to 30 percent, IgG3 about 5 to 8 percent, and IgG4 about 1 to 4 percent.

This matters because subclass patterns carry diagnostic weight. An isolated low IgG2 with a normal total IgG can signal a specific antibody deficiency. Very high IgG4 can support a diagnosis of IgG4-related disease, which is inflammatory rather than malignant. A total IgG within range can hide an abnormal subclass distribution.

Subclass testing, not total IgG, is the right test when the total is normal but symptoms suggest an antibody problem. This is one reason professional guidelines treat total IgG as a screening tool rather than a diagnostic one. The number is a starting point, not a verdict.

Comparison of Tests That Get Confused With Total IgG

Test What it detects Typical use Cancer link
Total serum IgG Sum of all IgG antibodies Screen for immune deficiency or excess Weak, indirect
Serum protein electrophoresis M-spike, clonal protein Suspected myeloma or MGUS Direct when M-spike found
Serum free light chains Light chain ratio Myeloma monitoring Direct for light chain disease
Quantitative immunoglobulins IgG, IgA, IgM levels Immune deficiency workup Indirect
Specific antibody titers Antibodies to one antigen Vaccine response, infection None
IgG subclasses IgG1 through IgG4 levels Suspected subclass deficiency None

This table shows why a single elevated IgG should not send anyone down a cancer pathway on its own. The tests with real cancer relevance are the electrophoresis and free light chain assays.

Timeline: What Happens After a High IgG Result

Time point Typical step Purpose
Day 0 Result flagged high Note the value and reference range
1 to 4 weeks Repeat total IgG Rule out transient rise
2 to 6 weeks Immunoglobulin panel and history Assess pattern and symptoms
4 to 8 weeks Protein electrophoresis if indicated Look for M-spike
Timing varies Free light chains or subclasses Refine diagnosis
Timing varies Referral to immunology or hematology Specialist evaluation

Timelines shift with symptoms. A high IgG alongside weight loss, night sweats, or bone pain moves faster. A mild elevation with no symptoms can be watched. The sequence is not fixed, and clinicians adjust it to the person.

Red Flags That Change the Picture

Unexplained weight loss, night sweats, or persistent bone pain. A known M-spike or abnormal free light chain ratio. Anemia, high calcium, or kidney dysfunction on routine labs. The same infection recurring or never resolving. Very high IgG above roughly 3,000 mg/dL on repeat testing. New neurological symptoms, which can signal paraneoplastic antibodies.

These bullets do not mean cancer is present. They mean the high IgG should not be dismissed as incidental. Each one shifts the next test from watchful waiting to active investigation. A clinician weighs them together, not as isolated triggers.

Practical Steps After a High IgG Result

First, verify the reference range and the unit. Confirm whether the result is in mg/dL or g/L, and check how far above the upper limit it sits. A 2022-era lab report still reflects the lab's own assay, so read the report text carefully.

Second, arrange a repeat test in two to six weeks if the elevation is mild. Many values normalize. A persistent elevation is more informative than a single reading.

Third, ask for a full immunoglobulin panel including IgA and IgM, plus protein electrophoresis when the elevation is substantial or symptoms exist. This combination finds patterns that total IgG misses.

Fourth, bring a symptom and medication history to the visit. Some drugs and chronic infections raise IgG. A complete history reduces unnecessary testing.

Fifth, see an immunologist or hematologist when the pattern is clonal or symptoms are unexplained. Do not order tumor markers hoping to rule cancer in or out; they are not designed for that.

What the Evidence Does Not Support

A high IgG does not prove cancer, and a normal IgG does not rule it out. That asymmetry is the key. The test measures immune activity, and cancer is only one possible driver among many.

No major clinical guideline uses total IgG as a cancer screening test. Screening recommendations come from bodies such as the US Preventive Services Task Force, and none include an IgG threshold for malignancy. The mechanisms here are stable, but the diagnostic limits are absolute: a total antibody count cannot locate or exclude a tumor.

The practical takeaway is to treat high IgG as a question, not an answer. Repeat it, pair it with the right follow-up tests, and let symptoms guide urgency. Cancer remains a low-probability explanation for most elevated results, and a measured approach keeps the workup proportionate.